Arbor Biotechnologies is a next-generation gene editing company based in Cambridge, MA. Combining the promise of CRISPR with advanced computational AI driven discovery, high throughput screening, and robust protein engineering approaches, the company's co-founders Feng Zhang and David Walt laid the groundwork for our proprietary discovery engine, which has yielded an extensive toolbox of gene editors, far exceeding the number of editors published in the literature to date. Arbor Bio envisions a future of gene editing that extends beyond simple knockdowns to include precision writing, precise excisions and large insertions. This affords the company the potential to treat a broad spectrum of patients, from ultra-rare to the most common genetic diseases. Guided by a deep understanding of the molecular basis of disease and the company's access to a unique suite of optimized editors, Arbor Bio is rapidly advancing it's discovery-stage programs with an initial focus on genomic diseases of the liver and CNS for which there are no existing functional cures. As the company advance toward the clinic with it's lead program in primary hyperoxaluria type I, Arbor Bio look to expand it's strategic partnerships around in vivo gene editing across multiple therapeutic areas and ex vivo cell therapy programs to broaden the reach of our novel nuclease technology.